Last reviewed · How we verify
Comparator: timolol
Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Comparator: timolol |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Beta-adrenergic antagonist (non-selective beta-blocker) |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body of the eye, which reduces the production and secretion of aqueous humor. This decrease in aqueous humor production leads to lower intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The drug does not significantly affect aqueous humor outflow.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Bradycardia (systemic absorption)
- Bronchospasm (in susceptible patients)
- Fatigue
Key clinical trials
- Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5% (PHASE3)
- Clinical Study Comparing Two Models of a Travoprost Intraocular Implant (PHASE3)
- A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration (PHASE2, PHASE3)
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension (PHASE3)
- Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® (PHASE4)
- Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: timolol CI brief — competitive landscape report
- Comparator: timolol updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI